BeyondSpring Reports Q3 2025 Financial Results with $4.9 Million Net Loss

BeyondSpring Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $4.9 million, compared to a loss of $4.6 million in the same period of the previous year. For the nine months ending September 30, 2025, the company recorded a net loss of $8.4 million, a significant improvement from the $12.0 million loss reported for the same period in 2024. The company continues to operate without generating revenue from product sales, as it remains focused on the development of its lead asset, Plinabulin, and other clinical-stage therapies.

Operating expenses for the third quarter of 2025 totaled $1.8 million, down from $2.4 million in the prior year, primarily due to reduced general and administrative costs. Research and development expenses increased to $1.0 million from $0.6 million, attributed to higher drug manufacturing costs and increased regulatory affairs expenses. The company’s accumulated deficit as of September 30, 2025, stood at $406.3 million, slightly down from $407.4 million at the end of 2024.

In terms of strategic developments, BeyondSpring has been actively pursuing partnerships and collaborations to enhance its product pipeline. The company has entered into agreements to sell portions of its Series A-1 Preferred Shares of SEED Therapeutics Inc. for approximately $35.4 million, with the first closing completed in February 2025. This divestiture is part of a broader strategy to optimize resources and focus on its core product development efforts. As of September 30, 2025, BeyondSpring and its subsidiaries owned approximately 38.03% of SEED, which is expected to decrease to 22.82% and 9.89% after subsequent closings.

Operationally, BeyondSpring has made strides in its clinical trials, particularly with Plinabulin, which is being studied in various cancer indications. The company has reported positive outcomes from its Phase 3 study of Plinabulin in combination with docetaxel for non-small cell lung cancer (NSCLC), demonstrating significant overall survival benefits. The company plans to file a New Drug Application (NDA) with the National Medical Products Administration (NMPA) in China for this indication. As of the latest report, BeyondSpring continues to explore additional funding options to support its ongoing clinical trials and operational needs, emphasizing the importance of securing capital to sustain its development activities.

Looking ahead, BeyondSpring anticipates continued operating losses as it invests in research and development. The company is actively seeking additional funding through various avenues, including equity and debt financing, to support its clinical development and commercialization efforts. The management remains optimistic about the potential of its product candidates, particularly Plinabulin, to address significant unmet medical needs in oncology.